Associated Factors for In-Hospital Mortality in Patients with Meningeal Cryptococcosis and HIV Infection at a Local Hospital in Lima, Peru
Juan C. Canessa, Diego Cabrera, Jonathan Eskenazi, Frine Samalvides
DOI: 10.4236/wja.2011.11002   PDF   HTML     4,879 Downloads   9,483 Views   Citations


Objective: To determine the associated factors for in-hospital mortality in patients with meningeal cryptococcosis and HIV infection at a local hospital in Lima, Perú. Materials and methods: We carried out a case-control study by reviewing the medical histories available at a local hospital in Lima, Peru. We determined the factors associated with mortality using a logistic regression model. Results: The information of 90 patients was analyzed, 37 dead and 53 alive. In the multivariate analysis we found two variables associated with mortality: Glasgow at admission (OR = 4.55 (1.61 – 12.20), p = 0.01) and serum antigen titer greater than 1024 (OR = 20.48 (1.6 – 261.04, p = 0.02). The protective factor found was a longer hospitalization stay (OR = 0.80 (0.69 – 0.93, p = 0.005).Conclusions: A low Glasgow score and serum antigen titer greater than 1024 are associated factors with mortality, whereas hospitalization length is a protective factor.

Share and Cite:

J. Canessa, D. Cabrera, J. Eskenazi and F. Samalvides, "Associated Factors for In-Hospital Mortality in Patients with Meningeal Cryptococcosis and HIV Infection at a Local Hospital in Lima, Peru," World Journal of AIDS, Vol. 1 No. 1, 2011, pp. 8-14. doi: 10.4236/wja.2011.11002.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. Jean, C. Fang and W. Shau, et al, “Cryptococcaemia: clinical features and prognostic factors,” Q J Med, Vol. 95, No. 8, 2002; pp. 511- 518.
[2] V. Lakshmi, T. Sudha and V. Teja, et al, “Prevalence of central nervous system cryptococcosis in human immudeficiency virus reactive hospitalized patients,” Indian Journal of Medical Science, Vol. 25, No. 2, 2007; pp. 146-149.
[3] P. Mwaba, J. Mwansa and C. Chintu, et al, “Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions,” Postgraduate Medical Journal, Vol. 77, No. 941, 2001; pp. 769-773. doi:10.1136/pmj.77.914.769
[4] B. Bustamante and D. Swinne, “Aislamiento de Cryptococcus neoformans variedad gattii en dos pacientes peruanos,” Revista Iberoamericana de Micologia, Vol. 15, 1998, pp. 22-24.
[5] C. Klock, M. Cerski and L. Goldani, “Histopathological aspects of neurocryptococcosis in HIV-infected patients: autopsy reports of 45 patients,” International Journal of Surgical Pathology, Vol. 17, No. 6, 2009; pp. 444-448.
[6] C. Charlier, F. Dromer and C. Lévêque, et al, “Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalities in HIV-positive patients in the HAART era,” PLoS Med, Vol. 3, No. 4, 2008; pp. 1-7.
[7] J. Jarvis and T. Harrison, “HIV-associated cryptococcal me- ningitis,” AIDS, Vol. 21, No. 16, 2007; pp. 2119-2129. doi:10.1097/QAD.0b013e3282a4a64d
[8] D. Cangelosi, L. De Carolis and L. Trombetta, et al, “Criptococosis meníngea asociada al SIDA. Análisis de los pacientes varones HIV(+) con criptococosis meníngea internados en la Sala 11 del Hospital Francisco J Mu?iz,” Revista de la Asociación Médica Argentina, Vol. 120, No. 3, 2007; pp. 25-30.
[9] T. Moreira, M. Ferreira and R. Marques Ribas, et al, “Criptococose: estudio clínico-epidemiológico, laboratorial e das variedades do fungo em 96 pacientes,” Revista da Sociedade Brasileira de Medicina Tropical, Vol. 39, No. 3, 2006, pp. 255-258. doi:10.1590/S0037-86822006000300005
[10] F. Dromer, S. Mathoulin-Pélissier and O. Launay, et al, “Determinants of disease presentation and outcome during cryptococcosis: the crypto A/D study,” PLoS Med, Vol. 4, No. 2, 2007; pp. 0297-0308.
[11] A. Brouwer, A. Rajanuwong and C. Wirongrong, et al, “Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial,” Lancet, Vol. 363, No.5, 2004, pp. 1764-1767.
[12] J. Lizarazo, M. Linares and C. de Bedout, et al, “Estudio clínico y epidemiológico de la criptococosis en Colombia: resultados de nueve a?os de la encuesta nacional,” Biomédica, Vol. 27, No. 1, 2007; pp. 94-109.
[13] A. Chakrabarti, “Epidemiology of central nervous system mycoses,” Neurology India, Vol. 55, No. 3, 2007, pp. 191-197.doi:10.4103/0028-3886.35679
[14] L. Trombetta, G. Poustis and A. Bocassi, et al, “Líquido cefalorraquídeo en pacientes con criptococosis asociada al SIDA,” Acta Bioquímica Clínica Latinoamericana, Vol. 42, No. 1, 2008; pp. 61-64.
[15] R. Andrade, “Características epidemiológico-clínicas de un grupo de pacientes con SIDA y meningoencefalitis criptococócica en el HNCH,” Tesis para optar por el grado de Médico Cirujano, UPCH: Lima - Perú,2001.
[16] H. Manji and R. Miller, “The neurology of HIV infection,” Journal of Neurology, Neurosurgery & Psychiatry, Vol. 75, Suppl. 1, 2004; pp. i29-i35. doi:10.1136/jnnp.2003.034348
[17] R. Thakur, S. Sarma and S. Kushwaha, “Prevalence of HIV- associated cryptococcal meningitis and utility of microbiological determinants for its diagnosis in a tertiary care center,” Indian Journal of Pathology and Microbiology, Vol. 51, No. 2, 2008; pp. 212-214. doi:10.4103/0377-4929.41689
[18] A. Comarú, C. Bittencourt and F. de Mattos, et al, “Cryptococcemia. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent,” Revista Iberoamericana de Micologia, Vol. 21, 2004, pp. 143-146.
[19] A. Kambugu, D. Meya and J. Rhein, et al, “Outcomes of Crypto- coccal Meningitis in Uganda before and after the availability of highly active antiretroviral therapy,” Clinical Infectious Diseases, 2008; Vol. 46, No. 6, pp. 1694-1701.
[20] B. Ojikutu, H. Zheng and R. Walensky, et al, “Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa,” South African Medical Journal, Vol. 98, No. 3, 2008, pp. 204-208.
[21] S. Subramanian and D. Mathai, “Clinical manifestations and management of cryptococcal infection,” Postgraduate Medical Journal, Vol. 51, Suppl. 1, 2005; pp. S21-S26.
[22] E. Cachay, J. Caperna and A. Sitapati, et al, “Utility of clinical assessment, imaging, and cryptococcal antigen titer to predict AIDS-related complicated forms of cryptococcal meningitis,” AIDS Research and Therapy, Vol. 7, No. 29, 2010; pp. 1-6.
[23] J. Graybill, J. Sobel, M. Saag, et al, “Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis,” Clinical Infectious Diseases, Vol. 30, No. 1, 2000; pp. 47-54. doi:10.1086/313603
[24] C. Darras-Joly, S. Chevret, M. Wolff, et al, “Cryptococcus neoformans infection in France: epidemiologic features of and early prognostic parameters for 76 patients who were infected with Human Immunodeficiency Virus,” Clinical Infectious Diseases, Vol. 23, No. 8, 1996; pp. 369-376. doi:10.1093/clinids/23.2.369
[25] S. Antinori, A. Ridolfo, M. Fasan, et al, “AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features, and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy,” HIV Medicine, Vol. 10, 2009; pp. 6-11. doi:10.1111/j.1468-1293.2008.00645.x
[26] S. Chottanapund, P. Singhasivanon and J. Kaewkungwal, et al, “Survival time of HIV-infected patients with cryptococcal meningitis,” Journal of The Medical Association of Thailand, Vol. 90, No. 10, 2007, pp. 2104-2111.
[27] T. Lu, H. Chang and L. Chen, et al, “Changes in causes of death and associated conditions among persons with HIV/AIDS after the introduction of highly active antiretroviral therapy in Taiwan,” Journal of the Formosan Medical Association, Vol. 105, No. 7, 2006; pp. 604-609. doi:10.1016/S0929-6646(09)60158-3
[28] B. Park, K. Wannemuehler and B. Marston, et al, “Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS,” AIDS, Vol. 23, No. 4, 2009; pp. 525-530. doi:10.1097/QAD.0b013e328322ffac
[29] J. Perfect, W. Dismukes and F. Dromer, et al, “Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America,” Clinical Infectious Diseases, Vol. 50, No. 1, 2010, pp. 291- 322.
[30] O. Lortholary, G. Poizat and V. Zeller, et al, “Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy,” AIDS, Vol. 20, No. 17, 2006, pp. 2183-2191. doi:10.1097/01.aids.0000252060.80704.68
[31] J. Perfect, “Cryptococcus neoformans,” Principles and practice of infectious diseases, Philadelphia, 2005, pp. 2997-3012.
[32] R. Sobhani, A. Basavaraj and A. Gupta, et al, “Mortality & clinical characteristics of hospitalized adult patients with HIV in Pune, India,” Indian Journal of Medical Research, Vol.126, No. 8, 2007; pp. 116-121.
[33] T. Warkentien and N. Crum-Cianflone, “An update on Cryptococcus among HIV-infected patients,” International Journal of STD & AIDS, Vol. 21, No. 10, 2010, pp. 679-684. doi:10.1258/ijsa.2010.010182
[34] P. Robinson, M. Bauer and M. Leal, et al, “Early mycological treatment failure in AIDS-associated cryptococcal meningitis,” Clinical Infectious Diseases, Vol. 28, No. 1, 1999, pp. 82-92. doi:10.1086/515074
[35] U. Jongwutiwes, S. Sungkanuparph and S. Kiertiburanakal, “Comparison of clinical features and survival between cryptococcosis in Human Immunodeficiency Virus (HIV)-positive and HIV-negative patients,” Japanese Journal of Infectious Disease, Vol. 61, 2008, pp. 111-115.
[36] R. Seaton, S. Naraqi and J. Wembri, et al, “Predictors of outcome in Cryptococcus neoformans var. gattii meningitis,” Q J Med, Vol. 89, 1996, pp. 423-428.
[37] J. Fan-Harvard, P. Yamaguchi and E. Smith, et al, “Diastolic hypertension in AIDS patients with cryptococcal meningitis,” American Journal of Medicine, Vol. 93, 1992, pp. 347-348. doi:10.1016/0002-9343(92)90245-7
[38] P. Imwidthaya, “N P. Cryptococcosis in AIDS,” Postgraduate Medical Journal, Vol. 76, 2000, pp. 85-88. doi:10.1136/pmj.76.892.85
[39] W. Powderly, G. Cloud and W. Dismukes, “Measurment of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis,” Clinical Infectious Diseases, Vol. 18, No. 5, 1992, pp. 789-792.
[40] A. Spinello, A. Radice and L. Galimberti, “The role of cryptococcal antigen assay in diagnosis and monitoring of cryptococcal meningitis,” Journal of Clinical Microbiology, Vol. 43, No. 11, 2005, pp. 5828-5829.
[41] P. Pappas, “Managing cryptococcal meningitis is about handling the pressure,” Clinical Infectious Diseases, Vol. 40, No. 1, 2005, pp. 480-482.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.